Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
GAITHERSBURG, Md. , July 06, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Sujata Dayal as a Class II director...
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
GAITHERSBURG, Md. , June 24, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics...
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
GAITHERSBURG, Md. , June 21, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety...
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threat Transaction to be...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
GAITHERSBURG, Md. , May 12, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via...
Emergent BioSolutions Reports Financial Results For First Quarter 2022
Reports Q1 2022 total revenues of $308M , in line with guidance, and Adjusted EBITDA of $36M Temporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG,...
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
GAITHERSBURG, Md. , April 08, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Provides Corporate Governance Update
Zsolt Harsanyi , Ph.D. Appointed Chairman of the Board Keith Katkin Appointed to the Board Eliminates Role of Executive Chairman Appoints New Chairs of Audit, Strategic Operations, and Scientific...
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
GAITHERSBURG, Md. , March 11, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety,...
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M , in line with prior guidance Updates full year 2022...
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
GAITHERSBURG, Md. , Feb. 07, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the...
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
Fuad El-Hibri to Retire After More Than 20 Years GAITHERSBURG, Md. , Jan. 14, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri , founder and...